The study did not provide details as to how patients with hsCRP levels >10mg/L were handled. The 2003 consensus statement by the Centers for Disease Control and Prevention and the American Heart Association suggests that many elevations at those levels are due to transient inflammation from minor infections and that patients should have the test repeated to properly determine their chronic hsCRP level.
The 17,802 participants, recruited from 1,300 clinical sites in 26 countries, were randomly assigned to 20 milligrams (mg) of rosuvastatin a day or a daily placebo. The study's independent data and safety monitoring board ended the trial in March 2008, more than two years ahead of schedule, when it determined that the study data indicated "unequivocal benefit of rosuvastatin" on coronary-related death and disability.
"Not only do we confirm that apparently healthy men and women with elevated hsCRP are at high risk of cardiovascular events, but we demonstrate that a simple therapy can reduce their risk of heart attack, stroke or cardiovascular death," Ridker said.
JUPITER included nearly 6,801 women and 5,119 members of minority groups in the randomized cohort.
"For the first time in a major statin prevention trial, we have clear evidence of benefits in women as well as men, in blacks and Hispanics as well as Caucasians, and perhaps most importantly, a substantial reduction in all-cause mortality," he said. "It appears hsCRP predicts high risk even when cholesterol is low."
However, that issue was not specifically tested in this study.
The benefits of rosuvastatin in people with elevated hsCRP extended across all subgroups evaluated, including those with low Framingham scores and those with LDL levels of less than 100mg/dL, Ridker said.
This is consistent wit
|SOURCE American Heart Association|
Copyright©2008 PR Newswire.
All rights reserved